4/24
04:14 pm
fgen
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology A
Medium
Report
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology A
4/24
04:02 pm
fgen
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology
Low
Report
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology
4/23
07:42 am
fgen
Pancreatic Cancer Pipeline Market Research 2024: Comprehensive Insights on More than 290 Companies and their Associated 300+ Pipeline Drugs [Yahoo! Finance]
Medium
Report
Pancreatic Cancer Pipeline Market Research 2024: Comprehensive Insights on More than 290 Companies and their Associated 300+ Pipeline Drugs [Yahoo! Finance]
4/16
12:34 pm
fgen
Kind Pharmaceuticals Announces Settlement [Yahoo! Finance]
Low
Report
Kind Pharmaceuticals Announces Settlement [Yahoo! Finance]
4/3
03:56 pm
fgen
FibroGen falls after early-stage data for prostate cancer drug [Seeking Alpha]
Low
Report
FibroGen falls after early-stage data for prostate cancer drug [Seeking Alpha]
4/2
05:53 pm
fgen
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer [Yahoo! Finance]
High
Report
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer [Yahoo! Finance]
4/2
05:46 pm
fgen
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
High
Report
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
3/26
07:09 am
fgen
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference [Yahoo! Finance]
Medium
Report
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference [Yahoo! Finance]
3/26
07:00 am
fgen
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference
Medium
Report
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference
3/11
07:35 am
fgen
FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer [Yahoo! Finance]
Medium
Report
FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer [Yahoo! Finance]
3/11
07:00 am
fgen
FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
Medium
Report
FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
2/29
08:27 am
fgen
FibroGen, Inc. (NASDAQ:FGEN) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
High
Report
FibroGen, Inc. (NASDAQ:FGEN) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/29
07:42 am
fgen
US$1.25: That's What Analysts Think FibroGen, Inc. (NASDAQ:FGEN) Is Worth After Its Latest Results [Yahoo! Finance]
High
Report
US$1.25: That's What Analysts Think FibroGen, Inc. (NASDAQ:FGEN) Is Worth After Its Latest Results [Yahoo! Finance]
2/27
09:31 am
fgen
Thinking about buying stock in Infobird, PubMatic, Hims & Hers Health, FibroGen, or Alpha Metallurgical Resources?
High
Report
Thinking about buying stock in Infobird, PubMatic, Hims & Hers Health, FibroGen, or Alpha Metallurgical Resources?
2/27
09:30 am
fgen
FibroGen, Inc. (NASDAQ: FGEN) had its "market perform" rating re-affirmed by analysts at William Blair.
High
Report
FibroGen, Inc. (NASDAQ: FGEN) had its "market perform" rating re-affirmed by analysts at William Blair.
2/26
04:55 pm
fgen
FibroGen Inc (FGEN) Reports Modest Revenue Growth and Reduced Net Loss in FY 2023 [Yahoo! Finance]
High
Report
FibroGen Inc (FGEN) Reports Modest Revenue Growth and Reduced Net Loss in FY 2023 [Yahoo! Finance]
2/26
04:46 pm
fgen
FibroGen GAAP EPS of -$0.57 misses by $0.14, revenue of $27.14M misses by $11.64M [Seeking Alpha]
Neutral
Report
FibroGen GAAP EPS of -$0.57 misses by $0.14, revenue of $27.14M misses by $11.64M [Seeking Alpha]
2/26
04:09 pm
fgen
FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea [Yahoo! Finance]
High
Report
FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea [Yahoo! Finance]
2/26
04:09 pm
fgen
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
High
Report
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
2/26
04:06 pm
fgen
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
Low
Report
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
2/26
04:05 pm
fgen
FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea
High
Report
FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea
2/20
07:08 am
fgen
FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
High
Report
FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
2/20
07:00 am
fgen
FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results
High
Report
FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results
2/5
07:20 am
fgen
FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024 [Yahoo! Finance]
High
Report
FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024 [Yahoo! Finance]
2/5
07:00 am
fgen
FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024
High
Report
FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024